文献速递神经免疫

克立咪唑在兔慢性脱髓鞘模型中诱导少突胶质祖细胞池耗竭与衰老

Clemastine Induces Oligodendrocyte Progenitor Pool Exhaustion and Senescence in the Context of Chronic Demyelination in a Rabbit Model.
PubMed 文献 · Ann Neurol · 2024-10-18

研究在兔白质脱髓鞘模型中给予口服克立咪唑(10mg/kg/天),发现全程56天给药增加少突胶质细胞生成,但较短疗程虽促进OPC向OL分化却未增加OL密度,与OPC池耗竭有关;延迟给药导致表达衰老标志物的活化OPC积累。作者认为需进一步研究这些效应是否在人类或其他促分化治疗中出现。

要点

  • 全程56天克立咪唑增加兔白质病变区少突胶质细胞生成。
  • 较短疗程未增加OL总密度,与OPC池耗竭有关。
  • 延迟给药导致表达衰老标志物的活化OPC积累。

核心结论

  • 克立咪唑在兔中虽能驱动少突胶质细胞分化,但妨碍祖细胞池补充、诱导衰老并促进小胶质细胞/巨噬细胞向促炎表型转化。
  • 作者认为这些效应是否在人类或其他促分化治疗中发生应进一步研究,数据提示治疗多发性硬化时需仔细考虑祖细胞动态。

研究设计与样本

  • 研究使用溶血卵磷脂在新西兰兔白质中诱导脱髓鞘,然后口服克立咪唑(10mg/kg/天)不同时长,评估病变区OPC和少突胶质细胞群体。
  • 研究类型原文未明确报告。

主要发现

  • 每日给予克立咪唑全程研究期(56天)增加白质病变区少突胶质细胞生成。
  • 较短疗程虽增强OPC向OL分化,但未增加OL总密度,因分化的祖细胞未得到补充,与OPC增殖减少有关。
  • 延迟给予克立咪唑导致表达衰老标志物的活化OPC积累。
  • 克立咪唑促进小胶质细胞/巨噬细胞向促炎表型转化。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者指出这些效应是否在人类或其他促分化治疗中发生应进一步研究。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Clemastine has emerged as a promising therapy for the restoration of neurologic function in patients with multiple sclerosis (MS). However, clemastine and other agents with prodifferentiative effects on oligodendrocyte progenitor cells (OPCs) in rodent models have underperformed in clinical trials. We hypothesized that the preclinical studies showed more robust effects because of the abundance of OPCs in rodent models. To better examine the therapeutic potential of clemastine, we examined its effect on demyelinated white matter lesions in rabbits, which exhibit progenitor densities and limited remyelination more closely matching those found in tissues from patients with MS. METHODS: We used lysolecithin to induce demyelination in white matter of New Zealand rabbits and then administered oral clemastine (10mg/kg/day) for various periods before assessing the OPC and oligodendrocyte (OL) populations in these lesions. RESULTS: Daily administration of clemastine for the full study period (56 days) increased oligodendrogenesis in white matter lesions. However, shorter durations of treatment failed to increase overall OL density despite enhancing OPC-to-OL differentiation. This effect was due to exhaustion of the OPC pool, as the differentiating progenitors were not replaced because of reduced OPC proliferation. Notably, delayed administration of clemastine led to an accumulation of activated OPCs expressing markers of senescence. INTERPRETATION: Although capable of driving OL differentiation, clemastine treatment in rabbits hampered progenitor pool replenishment, induced senescence, and promoted conversion of microglia/macrophages to a proinflammatory phenotype. Whether these effects would also occur in humans or with other prodifferentiative therapies should be studied further, but our data suggest the need to carefully consider progenitor dynamics in the treatment of MS. ANN NEUROL 2025;97:116-133.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Cooper JJM, Muthaiah R, Frost JR, et al. Clemastine Induces Oligodendrocyte Progenitor Pool Exhaustion and Senescence in the Context of Chronic Demyelination in a Rabbit Model. Ann Neurol. 2024. PMID: 39422297. doi:10.1002/ana.27098

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。